# Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

> **NCT07479108** · NA · COMPLETED · sponsor: **ADIUM** · enrollment: 32 (actual)

## Conditions studied

- Bioequivalance

## Interventions

- **DRUG:** Empagliflozin (Jardiance®)
- **DRUG:** Empagliflozin (oral)

## Key facts

- **NCT ID:** NCT07479108
- **Lead sponsor:** ADIUM
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-29
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479108, "Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07479108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*